For instance, our previous study indicated that DRD3 signalling in DCs reduces the presentation of tumour-derived antigens to CD8+ T-cells, thereby reducing the priming of tumour-specific lymphocytes and attenuating the anti-tumour immune response [24]. This evidence concerns the gene CD8A and neoplasm.